AGL anticorps (AA 357-387)
Aperçu rapide pour AGL anticorps (AA 357-387) (ABIN1882062)
Antigène
Voir toutes AGL AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 357-387
-
Purification
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
Immunogène
- This AGL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 357-387 amino acids from the Central region of human AGL.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- IF: 1:10~50. WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Date de péremption
- 6 months
-
-
-
: "Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice." dans: The Journal of biological chemistry, (2015) (PubMed).
: "Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, (2015) (PubMed).
: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin." dans: The Journal of biological chemistry, Vol. 285, Issue 33, pp. 25372-81, (2010) (PubMed).
: "Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis." dans: Muscle & nerve, Vol. 39, Issue 6, pp. 739-53, (2009) (PubMed).
: "Abnormal metabolism of glycogen phosphate as a cause for Lafora disease." dans: The Journal of biological chemistry, Vol. 283, Issue 49, pp. 33816-25, (2008) (PubMed).
: "A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease." dans: Genes & development, Vol. 21, Issue 19, pp. 2399-409, (2007) (PubMed).
: "Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III." dans: Journal of human genetics, Vol. 47, Issue 2, pp. 55-9, (2002) (PubMed).
: "Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region." dans: Genomics, Vol. 38, Issue 2, pp. 155-65, (1997) (PubMed).
: "T cell receptor usage by HLA-DQw8-specific T cell clones." dans: International immunology, Vol. 4, Issue 8, pp. 931-4, (1992) (PubMed).
: "Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranching enzyme." dans: The Journal of biological chemistry, Vol. 267, Issue 13, pp. 9294-9, (1992) (PubMed).
-
-
- AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))
-
Autre désignation
- AGL
-
Sujet
- AGL is a glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in the AGL gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing.
-
Poids moléculaire
- 174764
-
NCBI Accession
- NP_000019, NP_000633, NP_000634, NP_000635, NP_000636, NP_000637
-
UniProt
- P35573
-
Pathways
- Cellular Glucan Metabolic Process
Antigène
-